Berger Montague Investigates ADMA Biologics Board for Potential Breach of Duty
Law firm Berger Montague PC is investigating ADMA Biologics, Inc.'s Board of Directors for potential breaches of fiduciary duty. The probe centers on possible mismanagement within the company's leadership.
National law firm Berger Montague PC has announced an investigation into possible breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA). The investigation will examine the actions and decisions of the board members to determine if they have acted in ways that may have harmed the company or its shareholders.
ADMA Biologics is a biopharmaceutical company focused on the development and commercialization of human plasma-derived protein therapeutics. Allegations of fiduciary duty breaches often arise in cases involving significant financial losses, misleading statements, or corporate governance failures.
Berger Montague PC, known for its work in securities litigation, is seeking information from ADMA Biologics shareholders who may have relevant details about the board's conduct. The firm encourages any shareholder with concerns or knowledge pertaining to this matter to come forward.
This investigation is in its preliminary stages, and no determination of wrongdoing has been made. Further details are expected to emerge as the probe progresses.